跳至主要内容

New Animal Model Developed to Aid Zika Studies

 When battling emerging infectious diseases, finding a model that accurately recapitulates the pathogenesis of the infection is critical to developing effective therapeutic interventions. Yet, as most scientists can attest, the things that are the most critical are also most often the most difficult to obtain. An alternative animal model that mimics key features of the Zika virus infection, including its lingering presence in bodily fluids, has been developed at Texas Biomedical Research Institute in San Antonio.

Findings from the new study were published recently in Scientific Reports, in an article entitled “Experimental Zika Virus Inoculation in a New World Monkey Model Reproduces Key Features of the Human Infection.”

The research team found that acute infections in male marmosets, a New World monkey, resemble the human illness the Zika virus creates in people, including the presence of the virus in semen, saliva, and urine up to two weeks after the initial infection. The primary mode of transmission for the Zika virus is through mosquito bites. Moreover, according to the Centers for Disease Control and Prevention, the disease can be spread through sexual contact.

"Given the key similarities to human infections, a marmoset model of Zika may be useful for testing of new drug and vaccines," noted senior study investigator Jean Patterson, Ph.D., a Texas Biomedical Research Institute virologist. "Having an animal model of Zika infection to study may help us identify places where we might be able to block transmission." Like 80% of humans infected with the Zika virus, most of the nonhuman primates used in the current study lacked any apparent clinical symptoms. 

Zika Studies Animal Model Develop

Zika was first identified in Africa in the mid-20th century. It emerged as an infectious threat in the Western Hemisphere in 2015 in Brazil, where it made news for creating a spate of congenital disabilities, including the devastating brain anomaly microcephaly. A year ago, Texas saw its first documented cases of the Zika virus transmitted by local mosquitoes. The handful of cases along the Texas–Mexico border likely won't be the state's last encounter with this emerging virus, according to public health reports.

The Texas researchers looked at Zika infection in the common marmoset (Callithrix jacchus) and determined it to be a good model for studying the pathogenesis of the disease. Additionally, since the primates are small (about the size of a rat), they hold advantages over other animal models.

"That size can be an advantage when testing experimental vaccines and therapeutics that are available in limited quantities," noted co-senior study investigator Suzette Tardif, Ph.D., associate director of research at the Southwest National Primate Research Center at Texas Biomed.

These monkeys have been shown to have a high susceptibility to infection by a variety of pathogens, including Ebola and Lassa viruses that affect humans, making marmosets useful for drug and vaccine testing. Recently, Zika virus was discovered in serum and saliva from marmosets living in the wild in Brazil, suggesting that these nonhuman primates are "a potential reservoir for maintaining Zika virus in endemic countries," according to Dr. Patterson's report.

The research team was optimistic about their findings and is planning the next steps in testing various vaccines. Scientists around the world are working to discover more about how the disease is transmitted from pregnant mother to the fetus, including scientists at Texas Biomed, and this new model could prove to be invaluable in these studies.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...